Chen Liang
Impact in
- Cancer Research top 0.5%
- Cancer-related molecular mechanisms research
- Cancer, Hypoxia, and Metabolism
- Oncology top 0.5%
- Pancreatic and Hepatic Oncology Research
- Cancer Immunotherapy and Biomarkers
Papers in
- Oncology 68
- Pancreatic and Hepatic Oncology Research 49
- Cancer Immunotherapy and Biomarkers 13
-
- Cancer, Hypoxia, and Metabolism 14
- Cancer-related molecular mechanisms research 11
Chen Liang
144 papers receiving 7.8k citations
Hit Papers
Peers
Comparison fields: 5 of 136
- Cancer Research 2.4k
- Oncology 2.9k
- Immunology 1.7k
- Molecular Biology 4.5k
- Pulmonary and Respiratory Medicine 1.5k
Countries citing papers authored by Chen Liang
This map shows the geographic impact of Chen Liang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Chen Liang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Chen Liang more than expected).
Fields of papers citing papers by Chen Liang
This network shows the impact of papers produced by Chen Liang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Chen Liang. The network helps show where Chen Liang may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Chen Liang, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 0 | |
| 2 | 2025 | 1 | |
| 3 | 2025 | 0 | |
| 4 | 2025 | 0 | |
| 5 | 2024 | 11 | |
| 6 | 2024 | 7 | |
| 7 | 2024 | 11 | |
| 8 | 2024 | 9 | |
| 9 | 2023 | 0 | |
| 10 | Signaling pathways in cancer‐associated fibroblasts: recent advances and future perspectives Hit paper breakdown → | 2022 | 151 |
| 11 | 2022 | 39 | |
| 12 | 2021 | 13 | |
| 13 | 2021 | 53 | |
| 14 | 2020 | 116 | |
| 15 | 2019 | 78 | |
| 16 | 2019 | 120 | |
| 17 | 2018 | 53 | |
| 18 | 2017 | 46 | |
| 19 | 2016 | 76 | |
| 20 | Comparison of inhibitive effects of Curcumin and Calebin-A on human hepatoma cell line HepG2. | 2009 | 6 |
About Chen Liang
Chen Liang is a scholar working on Oncology, Cancer Research, Biological Psychiatry, Molecular Biology and Immunology, having authored 152 papers that have together received 7.9k indexed citations. Recurring topics across this work include Pancreatic and Hepatic Oncology Research (49 papers), Ferroptosis and cancer prognosis (18 papers), Epigenetics and DNA Methylation (17 papers), Cancer, Hypoxia, and Metabolism (14 papers), Cancer Immunotherapy and Biomarkers (13 papers), RNA modifications and cancer (12 papers), Cancer-related molecular mechanisms research (11 papers) and Gut microbiota and health (11 papers). The work is most often cited by research in Cancer Research (2.4k citations), Oncology (2.9k citations), Immunology (1.7k citations), Molecular Biology (4.5k citations) and Pulmonary and Respiratory Medicine (1.5k citations). Chen Liang has collaborated with scholars based in China, United States and Belgium. Frequent co-authors include Si Shi, Xianjun Yu, Jin Xu, Qingcai Meng, Jie Hua, Jiang Liu, Bo Zhang, Wei Wang, Bo Zhang and Xiaoqi Mao. Their work appears in journals such as Journal of Biological Chemistry, Cell Death and Disease, Frontiers in Oncology, Molecular Cancer and Cancer Letters.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.